On November 20, NAMD submitted comments to a CMS Request for Information regarding future directions for the Center for Medicare and Medicaid Innovation (CMMI). NAMD calls for a stronger partnership between states and CMMI to promote further demonstration and alternative payment model alignment, and provides several specific issue areas where this partnership can be applied […]
NAMD’s legislative and regulatory priority documents outline opportunities to modernize the federal rules governing Medicaid to ensure these comport with the realities and expectations for states to run high performing Medicaid programs. NAMD believes these modernizations – in federal statute and in federal regulation – can have a meaningful, positive impact for Medicaid enrollees. See […]
On May 18, NAMD submitted comments to the Health Resources and Services Administration (HRSA) in response to reopened provisions of a proposed rule on the 340B drug discount program. NAMD called for HRSA to maintain its initially proposed “penny pricing” method for 340B drugs, for HRSA to align the 340B ceiling price for new drugs […]
NAMD staff prepared a memo for Directors outlining key federal regulatory and legislative priorities for the remainder of the year. It provides a snapshot of major priorities for HHS, including completion of the final Medicaid managed care rule, systems work, and value-based purchasing. It also provides an assessment of legislation which is likely to impact […]
NAMD submitted comments to CMS on the final Medicaid covered outpatient drug rule. In the comments, NAMD calls attention to implementation timeline challenges posed by the rule and provides a suggested approach for handling line extension drugs. Read full letter.
NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these […]
NAMD submitted comments to the Health Resources and Services Administration (HRSA)’s proposed omnibus guidance addressing several aspects of the 340B drug discount program. Read the full comments.
NAMD provided written comments to the Health Resources and Services Administration on its proposed rule addressing ceiling prices and manufacturer civil monetary penalties in the 340B drug discount program. Read the full letter here.